These two peptides get compared constantly, usually on outcome numbers pulled from clinical press releases. From a bench perspective the more useful comparison is structural: they engage a different set of receptors, and that difference is what drives everything downstream.
The receptor sets are not the same
Tirzepatide is a dual agonist. It activates the GIP receptor and the GLP-1 receptor. Retatrutide is a triple agonist: GIP, GLP-1, and additionally the glucagon receptor (GCGR). That third receptor is the whole story.
| Tirzepatide | Retatrutide | |
|---|---|---|
| GLP-1 receptor | Yes | Yes |
| GIP receptor | Yes | Yes |
| Glucagon receptor | No | Yes |
| Residues | 39 | 39 |
| Molecular weight | 4813.53 g/mol | 4731.42 g/mol |
| Half-life extension | C20 fatty-diacid, albumin binding | C20 fatty-diacid, albumin binding |
Why the glucagon receptor matters at the bench
GLP-1 and GIP agonism act largely through incretin pathways. Adding glucagon-receptor activity brings hepatic energy expenditure into the model, which is why retatrutide studies frequently pair metabolic-rate measurements with the standard incretin readouts. If your assay only measures cAMP accumulation in a GLP-1R-expressing line, the two compounds will look far more similar than they are; the divergence shows up when GCGR-expressing cells are in the panel.
Signalling bias is the second axis
Tirzepatide is described in the literature as an imbalanced and biased agonist: relative to native GLP-1 it recruits beta-arrestin weakly at GLP-1R, which reduces receptor internalisation and prolongs surface signalling. That is a mechanistic difference, not a potency difference, and it is invisible to assays that only read cAMP. If you are comparing the two, run beta-arrestin recruitment alongside cAMP or the comparison is incomplete.
Practical notes for comparative work
- Use a receptor panel, not a single line. GIPR, GLP-1R and GCGR expressing cells, each measured separately.
- Pair cAMP accumulation with beta-arrestin recruitment and receptor-internalisation readouts.
- Both carry a C20 fatty-diacid chain and bind albumin; account for serum albumin in your buffer or apparent potency will shift between runs.
- Both are lyophilized and should reach room temperature before reconstitution. See the reconstitution calculator for volume maths.
Selected literature
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab. 2018;18:3-14.
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
- Coskun T et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist. Cell Metab. 2022;34(9):1234-1247.
Both are stocked as HPLC-verified reference standards: Tirzepatide 20 mg and Retatrutide 20 mg. For laboratory research use only.